Relay Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Relay Therapeutics, Inc. on June 6, 2025. The filing details the voting outcomes for three proposals regarding director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to stockholders. The results are as follows:
- Proposal 1: Election of Directors. Stockholders elected Alexis Borisy and Mark Murcko, Ph.D., to serve as Class II directors for a three-year term ending in 2028.
- Alexis Borisy: 80,716,409 votes For; 43,000,380 votes Withheld.
- Mark Murcko, Ph.D.: 79,505,170 votes For; 44,211,619 votes Withheld.
- Proposal 2: Advisory Vote on Executive Compensation. Stockholders approved the compensation of named executive officers on a non-binding basis.
- Votes For: 69,745,321
- Votes Against: 53,852,178
- Abstain: 119,290
- Proposal 3: Ratification of Independent Auditor. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 142,184,207
- Votes Against: 163,544
- Abstain: 113,516
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the significant number of broker non-votes (18,744,478) recorded for the director and compensation proposals.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 23, 2025, for detailed biographies of the elected directors and the rationale behind the executive compensation package.
- Confirm the tenure of the newly elected Class II directors, which extends until the 2028 annual meeting.